AbbVie Inc. (ABBV)
| Market Cap | 283.25B |
| Revenue (ttm) | 54.40B |
| Net Income (ttm) | 5.99B |
| Shares Out | 1.77B |
| EPS (ttm) | 3.37 |
| PE Ratio | 47.60 |
| Forward PE | 16.36 |
| Dividend | $6.20 (3.87%) |
| Ex-Dividend Date | Apr 12, 2024 |
| Volume | 3,444,442 |
| Open | 160.81 |
| Previous Close | 160.45 |
| Day's Range | 160.02 - 161.32 |
| 52-Week Range | 130.96 - 182.89 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 178.60 (+11.35%) |
| Earnings Date | Apr 26, 2024 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; E... [Read more]
Financial Performance
In 2023, AbbVie's revenue was $54.32 billion, a decrease of -6.44% compared to the previous year's $58.05 billion. Earnings were $4.86 billion, a decrease of -58.91%.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $178.6, which is an increase of 11.35% from the latest price.
News
Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million
ATLANTA--(BUSINESS WIRE)---- $ABBV #15_Percent_Interest_Bearing_Preferred_Stock--Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of ...
AbbVie to Present at the Bank of America Securities Healthcare Conference
NORTH CHICAGO, Ill. , May 6, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 15, 2024.
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
AbbVie has two successors that could offset the losses from its blockbuster drug Humira. Meanwhile, UnitedHealth Group's CEO will testify on Capitol Hill.
FTC challenges ‘bogus' patents on Ozempic, other drugs that ‘block competition'
WASHINGTON — Federal regulators are challenging patents on 20 brand-name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting indu...
AbbVie Stock Falls As Company Warns of Continued Humira Sales Slump
Shares of AbbVie (ABBV) slumped Friday as the pharmaceutical firm warned of deeper declines in sales of its blockbuster arthritis drug, Humira, because of competition from close copies known as biosim...
AbbVie's Q1 earnings beat expectations as arthritis drug boosts growth
Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie's earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 pe...
AbbVie Raises Earnings Guidance Even as Humira Sales Continue to Fall
AbbVie reports better-than-expected adjusted earnings in the first quarter.
AbbVie lifts profit forecast after Skyrizi sales beat expectations
AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter.
AbbVie's first-quarter results top expectations as arthritis drugs fuel growth
AbbVie Inc. on Friday reported first-quarter results that beat expectations, even as sales of blockbuster autoimmune drug Humira continued to fall amid new, lower-cost competition.
AbbVie Reports First-Quarter 2024 Financial Results
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08...
AbbVie's skin disease drug found to be more effective than Regeneron's Dupixent in study
AbbVie said on Thursday its drug, Rinvoq, for treating a type of inflammatory skin condition was found to be more effective than Regeneron Pharmaceuticals and Sanofi's Dupixent in a late-stage head-to...
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Upadacitinib demonstrated superiority versus dupilumab in primary endpoint of simultaneous achievement of near complete skin clearance (EASI 90) and no to little itch (WP-NRS 0/1) at Week 161 LEVEL UP...
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Consumers Can Apply for a Chance to Be Featured in Upcoming Campaigns for BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics Loyalty Rewards Program IRVINE, Calif....
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
− Results from the Phase 3 SELECT-GCA study showed 46 percent of patients with giant cell arteritis (GCA) who were treated with upadacitinib (RINVOQ®; 15 mg) with a 26-week steroid taper regimen a...
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL) today announced a collaboration with AbbVie to co-develop and commercialize up to six therapeutic products across multipl...
These four halal, Shariah-compliant stocks are best buys after Eid al-Fitr
If you want to invest in some new halal stocks, you know that finding companies compliant with Shariah law can be complicated.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of AbbVie Inc. (“Abb...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) investors concerning the Company's possible ...
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine
- Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine - Seventy percent of ...
The Law Offices of Frank R. Cruz Announces Investigation of AbbVie Inc. (ABBV) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of AbbVie Inc. (“AbbVie” or the “Company”) (NYSE: ABBV) on behalf of investors concerning the Company's possib...
SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne
From the makers of BOTOX ® Cosmetic, two new SkinMedica ® acne products help address skin blemishes and can be combined with in-office DiamondGlow ® IRVINE, Calif. , April 9, 2024 /PRNewswire/ -- All...
Is Johnson & Johnson Stock A Better Pick Over AbbVie?
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer AbbVie (NYSE: ABBV). AbbVie ABBV trades at a higher valuation of 5.5x trailing rev...
AbbVie to Host First-Quarter 2024 Earnings Conference Call
NORTH CHICAGO, Ill. , April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens.
Top three US healthcare stocks to buy in April
As we look forward to celebrating World Health Day on April 7th, these are the top three healthcare US companies we think you should be watching for your financial health. 1. Lilly (Eli) & Co.
Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®
Offering $200 Off the First CoolSculpting® Treatment IRVINE, Calif. , April 3, 2024 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV) is announcing its second annual CoolMonth celebr...